1. Market Research
  2. > Bronchiolitis Obliterans - Pipeline Review, H2 2013

Bronchiolitis Obliterans - Pipeline Review, H2 2013

  • December 2013
  • -
  • Global Markets Direct
  • -
  • 44 pages

Bronchiolitis Obliterans - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Bronchiolitis Obliterans - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Bronchiolitis Obliterans, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bronchiolitis Obliterans. Bronchiolitis Obliterans - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Bronchiolitis Obliterans.
- A review of the Bronchiolitis Obliterans products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Bronchiolitis Obliterans pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Bronchiolitis Obliterans.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Bronchiolitis Obliterans pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Bronchiolitis Obliterans - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Bronchiolitis Obliterans Overview 6
Therapeutics Development 7
Pipeline Products for Bronchiolitis Obliterans - Overview 7
Pipeline Products for Bronchiolitis Obliterans - Comparative Analysis 8
Bronchiolitis Obliterans - Therapeutics under Development by Companies 9
Bronchiolitis Obliterans - Therapeutics under Investigation by Universities/Institutes 10
Bronchiolitis Obliterans - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Bronchiolitis Obliterans - Products under Development by Companies 13
Bronchiolitis Obliterans - Products under Investigation by Universities/Institutes 14
Bronchiolitis Obliterans - Companies Involved in Therapeutics Development 15
PARI Pharma GmbH 15
Pacific Therapeutics Ltd. 17
Bronchiolitis Obliterans - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Combination Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Assessment by Therapeutic Class 28
Drug Profiles 30
cyclosporine - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
cyclosporine liposomal - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
bortezomib - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
interferon gamma-1b - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
(pentoxifylline + N-acetylcysteine) - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
Bronchiolitis Obliterans - Recent Pipeline Updates 37
Bronchiolitis Obliterans - Dormant Projects 39
Bronchiolitis Obliterans - Product Development Milestones 40
Featured News and Press Releases 40
Nov 13, 2012: Pacific Therapeutics Announces Positive Results From Phase I Trial Of PTL-202 40
Aug 22, 2012: Pacific Therapeutics Completes Enrollment In Clinical Trial Of PTL-202 40
Jan 10, 2012: Pacific Therapeutics Provides Update On Development Of Lead Drug Candidate, PTL-202 40
Feb 11, 2010: PARI Pharma Enrolls First Patient In Phase IIb Study Of L-CsA 41
Jun 02, 2009: PARI Pharma Reports Successful Phase Ib Clinical Results For Inhaled Liposomal Cyclosporine A And Gains FDA Orphan Drug Designation For The Prevention And Treatment Of Bronchiolitis Obliterans 41
Appendix 43
Methodology 43
Coverage 43
Secondary Research 43
Primary Research 43
Expert Panel Validation 43
Contact Us 44
Disclaimer 44



List of Tables

Number of Products under Development for Bronchiolitis Obliterans, H2 2013 7
Number of Products under Development for Bronchiolitis Obliterans - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Number of Products under Investigation by Universities/Institutes, H2 2013 10
Comparative Analysis by Late Stage Development, H2 2013 11
Comparative Analysis by Clinical Stage Development, H2 2013 12
Products under Development by Companies, H2 2013 13
Products under Investigation by Universities/Institutes, H2 2013 14
Bronchiolitis Obliterans - Pipeline by PARI Pharma GmbH, H2 2013 15
Bronchiolitis Obliterans - Pipeline by APT Pharmaceuticals, Inc. (Inactive), H2 2013 16
Bronchiolitis Obliterans - Pipeline by Pacific Therapeutics Ltd., H2 2013 17
Assessment by Monotherapy Products, H2 2013 18
Assessment by Combination Products, H2 2013 19
Number of Products by Stage and Target, H2 2013 21
Number of Products by Stage and Mechanism of Action, H2 2013 23
Number of Products by Stage and Route of Administration, H2 2013 25
Number of Products by Stage and Molecule Type, H2 2013 27
Number of Products by Stage and Therapeutic Class, H2 2013 29
Bronchiolitis Obliterans Therapeutics - Recent Pipeline Updates, H2 2013 37
Bronchiolitis Obliterans - Dormant Projects, H2 2013 39



List of Figures

Number of Products under Development for Bronchiolitis Obliterans, H2 2013 7
Number of Products under Development for Bronchiolitis Obliterans - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Comparative Analysis by Clinical Stage Development, H2 2013 12
Assessment by Monotherapy Products, H2 2013 18
Number of Products by Top 10 Target, H2 2013 20
Number of Products by Stage and Top 10 Target, H2 2013 21
Number of Products by Top 10 Mechanism of Action, H2 2013 22
Number of Products by Stage and Top 10 Mechanism of Action, H2 2013 23
Number of Products by Top 10 Route of Administration, H2 2013 24
Number of Products by Stage and Top 10 Route of Administration, H2 2013 25
Number of Products by Top 10 Molecule Type, H2 2013 26
Number of Products by Stage and Top 10 Molecule Type, H2 2013 27
Number of Products by Top 10 Therapeutic Class, H2 2013 28
Number of Products by Stage and Top 10 Therapeutic Class, H2 2013 29



Companies Mentioned

PARI Pharma GmbH
Pacific Therapeutics Ltd.

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.